Breaking into healthcare investment banking

What healthcare investment banking covers, and why candidates pick it

Healthcare is the one coverage group where the analyst sitting next to you might spend Monday on a hospital roll-up and Tuesday on a company with no revenue, no earnings, and a market value built entirely on what a clinical trial says in eighteen months. That range is the pitch and the challenge at once. A consumer banker learns one grammar of valuation and applies it across brands. A healthcare banker has to hold several grammars in their head simultaneously, because biopharma, medical devices, life science tools, hospitals, insurers, and healthcare software do not share a business model, a growth driver, or a way of getting valued.

Candidates gravitate to the group for a mix of reasons, and interviewers can tell the difference between the honest ones and the rehearsed ones. Some come in with a science background and want a seat where that background is actually useful, since healthcare is one of the few coverage groups where knowing what a primary endpoint is, or what a companion diagnostic does, gives you a real edge in a live deal discussion. Others come in cold, with no science background at all, and pick the group because the analytical range is wider than anywhere else on the floor: discounted cash flow one week, a probability-weighted valuation the next, unit economics on a physician-practice roll-up the week after that. Both paths are legitimate. What is not legitimate, and what interviewers probe for immediately, is the answer that stops at "I want to help patients." That sentiment is fine as motivation and useless as an interview answer, because it says nothing about why you'd choose the finance seat over medical school, nursing, or public health. The full framework for answering this question, including what a strong answer sounds like and why the generic version collapses under a follow-up, is in how to answer why healthcare.

There's also a resilience argument that candidates reach for, and it holds up better than most sector pitches: people do not stop getting sick, having elective procedures deferred only so long, or paying insurance premiums because the broader economy is soft. Healthcare demand is less cyclical than consumer discretionary spending or industrial capital expenditure, which means healthcare deal flow tends to hold up better across a downturn than sectors tied directly to consumer confidence or corporate capex budgets. That's a real, defensible point, not a platitude, and it's worth having ready.

The client base is also unusually varied, which is part of what makes the seat interesting and part of what makes it hard. In one week you might sit across from a corporate development team at a large pharmaceutical company thinking in decades about patent expiration, a founder-CEO of a fifteen-person biotech burning cash toward its next clinical readout, a private equity-backed physician practice platform negotiating payor contracts, and a family that has run a regional home health business for two generations and is weighing a sale for the first time. Each of those conversations requires a different vocabulary and a different sense of what the counterparty actually cares about, and interviewers use that variety as a proxy for whether a candidate can adapt rather than apply one script everywhere.

How banks organize healthcare coverage

Most banks run healthcare as a single vertical coverage group, the way they run technology, media and telecom, or industrials, rather than splitting it across product groups. Inside that vertical, banks typically staff separate teams by sub-sector, because the client relationships, the regulatory vocabulary, and the buyer universe are different enough that generalist coverage stops working past a certain size. A biopharma team spends its time with management teams thinking about clinical catalysts, cash runway, and partnering strategy. A medtech and tools team thinks about reimbursement codes, distribution channels, and product cycles. A healthcare services team thinks about payor mix, provider networks, and regulatory approvals for transactions involving patient care. A larger bank might have four or five distinct sub-teams under one healthcare umbrella; a smaller bank or boutique might run two, biopharma and everything else.

This matters for recruiting because "healthcare group" on a bank's org chart can mean different things depending on where you land inside it. It is worth asking, in an interview or a coffee chat, which sub-sector a group leans toward, because a group that is heavily biopharma-weighted will have you underwriting risk on binary clinical events from day one, while a group weighted toward services and payors will have you doing more conventional cash-flow-based M&A and LBO work. Neither is better, but they are different jobs wearing the same "healthcare" label. The full map of the sub-sectors themselves, with a side-by-side comparison of business model and valuation approach, is in the healthcare sub-sector map, and the day-to-day of the job across those sub-sectors is covered in what healthcare investment bankers actually do.

Junior staffing tends to follow the same split, though banks vary in how rigidly they enforce it. Some banks rotate first-year analysts across the sub-teams before letting them specialize, on the theory that broad exposure produces better generalist judgment before someone commits to a lane. Others staff analysts into a sub-team from day one, on the theory that the vocabulary gap between, say, biopharma and provider services is wide enough that switching mid-year slows everyone down. Either way, the sub-sector split is the organizing fact of the group, and a candidate who can name it unprompted signals real research into the seat rather than a generic "I want healthcare" answer copied across every bank on a target list.

Healthcare also intersects constantly with other groups. Financial sponsors are heavy buyers of physician-practice platforms, home health businesses, and medtech carve-outs, so healthcare bankers work alongside a financial sponsors coverage team on almost every services-side leveraged buyout. Equity capital markets partners with biopharma coverage constantly, because biotech is one of the most IPO- and follow-on-heavy sectors in the market, a dynamic covered in full in biotech IPOs and follow-on offerings. If you want the mechanics of how financial sponsors groups work in general, that's covered in the financial sponsors group guide.

The sub-sector landscape

The single hardest thing about healthcare coverage, and the single most common interview trap, is treating the sector as one thing. It isn't. Below is the map interviewers expect you to already have internalized before they ask a single valuation question.

Two sub-sectors deserve a second look because they are the ones interviewers lean on hardest. Biopharma is the outlier of the whole sector: it is the only sub-sector where a company can be worth billions with zero revenue, because the value sits entirely in a pipeline of drug candidates working through clinical trials. Standard multiples have nothing to divide by, so the sector uses its own valuation logic, covered fully in how biotech companies are valued, and the business model underneath it, including why a pipeline is the real asset and why patents expiring is a real threat to a large company's revenue base, is in pharma business models, pipelines, and patent cliffs.

Medtech and life science tools, by contrast, look far more like an industrials business than a biopharma one: once a device or instrument is on the market, it throws off real, recurring cash flow from consumables and service contracts, and conventional multiples work fine. The mechanics of that model, and why it's a meaningfully different interview conversation than biotech valuation, get a full explainer of their own elsewhere in this guide.

Providers and payors run on an entirely different engine again: reimbursement. Nobody in this part of the sector sets their own price the way a consumer brand does. A hospital gets paid what a payor's contract says it gets paid, and a payor's profitability depends on how well its premium revenue covers the claims it pays out. That whole dynamic, and the volume-versus-rate framework interviewers use to test whether you understand it, also gets a dedicated explainer later in this guide.

Healthcare IT sits slightly apart from the other five, because it is the sub-sector that looks most like a conventional software business layered on top of a healthcare customer. A company selling scheduling, billing, or clinical-record software to hospitals and physician groups is valued the way any subscription software business is valued elsewhere, on recurring revenue and retention, but its growth is still gated by the same regulatory and reimbursement dynamics that shape its customers' budgets. Candidates sometimes default to treating HCIT as pure software and miss that its sales cycles, customer concentration, and budget cycles are downstream of hospital and payor economics, not independent of them.

How valuation differs in this group

The reason healthcare has its own valuation chapter, separate from every other coverage group's guide, is that a single DCF-and-comps toolkit does not travel across the sector's sub-sectors. Interviewers use this fact constantly: they will hand you a company, sometimes deliberately without naming the sub-sector clearly, and watch whether you reach for the right tool.

For an approved, commercial-stage biopharma company or a profitable medtech company, the toolkit looks conventional: DCF, trading comps, precedent transactions, the same three-legged stool used everywhere else in banking. The complication starts the moment a company has clinical-stage assets in the pipeline that haven't reached the market yet, which describes almost every biotech and a meaningful chunk of every large pharma company's future value. For those assets, cash flows are binary and contingent on events that haven't happened: does the trial succeed, does the drug get approved, does it get reimbursed once it's approved. A plain DCF assumes cash flows happen; it has no native way to say "there's a real chance these cash flows never happen at all." The sector's answer is risk-adjusted net present value, which explicitly multiplies each future cash flow scenario by the probability it actually occurs before discounting it back, rather than pretending the future is a single knowable path. The full mechanic, worked through with a simplified example, is in how biotech companies are valued.

A second valuation wrinkle is more subtle and shows up constantly in provider and payor interviews: revenue is a function of two separate levers, volume and rate, and a business can grow revenue by moving either one, with very different implications for durability and quality of earnings. A hospital system that grows by treating more patients is growing in a way that scales with facilities and staffing. A hospital system that grows because it renegotiated higher reimbursement rates with a major payor is growing in a way that is largely a one-time step change, not a repeatable engine. Interviewers ask candidates to decompose revenue growth into volume and rate specifically because so many candidates give a single blended growth number and stop there.

A third wrinkle, specific to large pharma, is that a single conventional DCF on the whole company understates how the sector actually thinks about value. A large pharma company is really a portfolio of individually risky assets, some already generating cash on-market and declining toward a known patent expiration date, others still moving through clinical trials with genuinely uncertain outcomes. Analysts and bankers commonly build a sum-of-the-parts model, valuing each major on-market product and each significant pipeline asset separately, sometimes with its own risk-adjusted NPV, and adding the pieces together rather than treating total company cash flow as one smooth line. It's a more granular version of the same idea covered in pharma business models, pipelines, and patent cliffs: a pharma company's value is really the sum of a shrinking base of mature products and a growing (and uncertain) set of future ones, and collapsing that into a single blended growth rate hides the real story.

Deal structures and dynamics you must know

Healthcare M&A uses a wider set of deal structures than most coverage groups, and almost all of the extra structures exist for the same reason: to price and share risk that a plain cash-for-stock deal cannot handle well.

Licensing and partnership deals are the sector's most distinctive structure. Instead of buying a company outright, a large pharma company will license the rights to a specific drug candidate from a smaller biotech, paying an upfront cash payment plus a series of milestone payments triggered by clinical, regulatory, and commercial events, plus a royalty on eventual sales. This lets the larger company gain access to a promising asset without paying the full acquisition price for a whole company, and lets the smaller company fund its business without giving up full ownership of its pipeline. The full structure, including why milestones are staged the way they are, is in healthcare deal structures: licensing and milestones.

A related structure is the contingent value right, used inside an outright M&A deal rather than a licensing deal, to bridge a valuation gap on pipeline assets whose worth depends on a future clinical or regulatory outcome. The buyer pays a base price today and issues a separate security to the seller's shareholders that pays out additional consideration only if the specified event occurs. It's the same economic logic as an earn-out in a general M&A deal, adapted to healthcare's specific binary-outcome risk.

Provider and services M&A runs on a completely different structure: the roll-up. Financial sponsors and larger platforms acquire a series of smaller physician practices, home health agencies, or specialty clinics, integrate their back offices, and sell the combined, larger platform at a higher multiple than any of the pieces commanded on their own, a dynamic driven by multiple arbitrage and by real operating synergies in billing, scheduling, and payor contracting. This overlaps heavily with financial sponsors work, and the LBO mechanics behind it are the same core mechanics covered in the financial sponsors group guide.

Capital markets structures matter here too, and biopharma is the clearest example. A clinical-stage biotech typically funds years of losses before it ever has a product to sell, and it does so almost entirely through equity: an IPO priced on the strength of its pipeline and upcoming catalysts, followed by one or more follow-on offerings timed around trial readouts, and sometimes a private placement from specialist healthcare investors when the company wants to raise capital without a fully marketed public offering. Debt rarely works for a company with no cash flow to service it, so the sector leans on equity dilution as the standard cost of staying funded, a dynamic covered fully in biotech IPOs and follow-on offerings.

Regulatory risk overlays almost every one of these structures in a way that other sectors don't experience nearly as intensely. FDA approval risk sits underneath every biopharma valuation and every licensing deal's milestone schedule. Antitrust review is unusually aggressive in provider consolidation, because regulators watch local market concentration in hospital and physician mergers closely, on the theory that healthcare markets are geographically constrained in a way that most consumer markets are not. The full landscape of regulatory considerations specific to this sector is in regulatory risk in healthcare M&A.

How interviews for this group differ

A generalist banking interview tests DCF mechanics, accretion/dilution, and a handful of accounting questions that apply everywhere. A healthcare interview tests all of that and then layers sector-specific judgment on top, and the layering is deliberate: interviewers use healthcare specifically because it's a good filter for whether a candidate can hold two different valuation frameworks in their head and know when to switch between them.

Expect three kinds of extra questions beyond the generalist core. First, sub-sector fluency: can you explain, without prompting, why a pre-revenue biotech and a profitable medtech company get valued completely differently, and why that isn't a contradiction. Second, mechanism questions about the sector's own vocabulary: what a patent cliff is, why reimbursement rate and patient volume are different growth levers, what a CVR does and why it exists. Third, judgment questions dressed up as pitches: "pitch me a healthcare stock" is a favorite superday question precisely because a weak candidate will apply a generic pitch structure without matching the valuation method to the sub-sector, using a P/E multiple on a company with no earnings, for instance. The full pitch framework, including how to avoid that exact trap, is in pitching a healthcare stock.

Healthcare interviewers are also more tolerant than most of candidates without a science background, as long as the candidate is honest about it and shows they've done the work to understand the mechanisms rather than the underlying biology. Nobody expects an undergraduate finance major to explain the biochemistry of a monoclonal antibody. Everyone expects that same candidate to know what a Phase 3 trial is, why it matters more to a valuation than a Phase 1 readout, and why a company might partner away half of a drug's value rather than fund late-stage trials alone.

A handful of accounting questions are also distinctive enough to the sector that they show up repeatedly. One is how acquired research and development is treated in an acquisition: when a pharma company buys a biotech, the in-process R&D it acquires has to be recognized on the balance sheet as an intangible asset at fair value, separate from goodwill, and it stays there rather than being expensed immediately, which surprises candidates who assume all research spending simply flows through the income statement the way a target's own ongoing R&D does. Another is R&D expensing itself: unlike a manufacturing asset, a company's own research spending is expensed as incurred rather than capitalized, which is exactly why an early-stage biotech's income statement shows large losses even though the pipeline it is building may be worth far more than its accumulated losses suggest.

The fit question gets asked with unusual intensity in this group, because interviewers have heard "I want to help patients" so many times that it has become a negative signal rather than a positive one. A specific, credible answer that references the analytical range across sub-sectors, the resilience of demand, or genuine interest in the pace of scientific and regulatory change will stand out simply by not being generic. The complete framework for that answer is in how to answer why healthcare.

Where a healthcare banking career goes

Healthcare coverage experience is unusually portable because it is scarce. Sector fluency in biopharma valuation, reimbursement mechanics, or regulatory risk takes real time to build, and healthcare-focused funds on the buy side would rather hire someone who already speaks the language than train a generalist from scratch. That scarcity is what makes the group's exit opportunities distinctive: healthcare-dedicated private equity funds, long-short healthcare hedge funds, and biotech- or medtech-focused venture and growth equity firms recruit directly and specifically out of healthcare banking groups, in a way that a generalist coverage banker doesn't experience to the same degree. The complete landscape of where healthcare bankers go next, and why the sector specialization is treated as a credential rather than a limitation, is in healthcare exit opportunities.

The group is not for everyone. It asks you to be comfortable with genuine uncertainty, since a trial readout can erase a valuation overnight in a way a same-store-sales miss in consumer retail never will, and it asks you to keep learning new vocabulary as you move between sub-sectors. For candidates who find that range energizing rather than exhausting, it's one of the more durable, differentiated seats in the industry to build a career from. The full interview question bank for the group, covering fit, valuation mechanics, sector accounting, and market judgment, is at the healthcare investment banking questions page.